StockWatch
·

FRACTAL Q2 FY27 Results

FRACTALQ2 FY27 Results
Filing
Result:Good· Market: Surged

Outlook: Optimistic · Guidance: None

MetricValue (₹ Cr)vs Q1 FY27
Revenue956.504.8%
Total Income985.305.7%
Expenditure858.905.0%
PBT126.404.6%
Net Profit79.209.5%
OPM15.69%0.73pp
NPM8.04%0.28pp
EPS4.719.3%
View full financials

IT/services core metric—revenue and PAT grew sequentially (₹912.5cr→₹956.5cr, ₹72cr→₹79.2cr) with margins holding flat (OPM ~15.7% vs ~15.66% in Q1FY27), a healthy but not standout continuation given the ongoing TMT-vertical overhang flagged by analysts.

FRACTAL · Q2 FY27 · THE VERDICT

Scale Achieved, Margins at Risk: Where Fractal's AI Bet Really Sits

Fractal crossed $100M in quarterly revenue and grew profit 139% YoY, but a sharp 225 basis point gross margin compression forces the real question: can management recover margins in H2, or is the AI talent investment a multi-quarter drag?

06 Nov 2026 · 6 min read
Reported Net Profit

₹79.2 Cr

+139% YoY

Excluding Qure.ai loss

~₹102 Cr

~10.7% NPM

Gross Margin

44%

−225 bps YoY

EBITDA Margin

16.2%

+123 bps despite gross margin hit

Fractal hit a milestone in Q2: ₹956.5 crore in revenue (~$115 million USD), up 20% year-over-year and 4.8% sequentially. Profit surged 139% to ₹79.2 crore. But that top-line momentum masks the quarter's central tension—a steep drop in gross margins that has forced management to delay recovery guidance from near-term to H2 FY27. Investors are now placing the entire valuation on execution of that H2 margin rebound.

The profit breakdown: reported vs. adjusted

Reported net profit of ₹79.2 crore includes a ₹23 crore loss from Fractal's 31.5% stake in Qure.ai, the AI diagnostics company undergoing restructuring after a USAID funding shutdown. Strip out that associate loss, and underlying net profit is roughly ₹102 crore, or 10.7% of revenue—the organic profitability baseline. The reported 8.0% NPM conflates margin expansion from SG&A discipline (real) with a temporary investment drag (expected to normalize).

Q2 FY27 Net Profit, ₹ Cr
038.0876.16114.2479.2Reported23Qure loss102Adjusted
Qure.ai loss is 23% of reported profit. Adjusted profit isolates the core business.

Gross margin: the hinge

Gross margin slid to 44%, down 225 basis points year-over-year. Management attributed the hit to heavy investment in forward-deployed engineers (FDE)—AI talent stationed inside client organizations to accelerate outcomes and deepen engagement. The drag is material: roughly 279 basis points of the 225 basis point total decline. Delivery expense as a share of revenue jumped to 56% from 51% a year ago.

We have invested ahead of the curve which is reflected in the gross margin for the quarter, while operating leverage has continued in SG&A. There is a short-term impact as we have invested in AI engineering talent.

The bet: those FDE hires are not yet billing at full utilization, but they will drive future revenue growth and competitive positioning. Management guided for gross margin recovery in Q3 and Q4 as these engineers deploy and begin generating revenue. Meanwhile, SG&A margin improved sharply to 23.6% of revenue (down from 27% prior quarter), showing cost discipline, and enabling EBITDA margin to expand 123 basis points to 16.2% despite the gross margin pressure.

Management claims vs. what the numbers show

Crossed $100M USD revenue threshold

Q2 revenue ₹956.5 Cr ≈ $115M USD, up 20% YoY and 4.8% QoQ

Supported

Adjusted EBITDA grew 30% YoY vs 20% revenue growth

EBITDA margin 16.2%, up 123bps YoY; absolute EBITDA growth ~30% implied by margin expansion and revenue growth

Supported

Gross margin down 225bps due to AI talent investment

Gross margin 44%, down 225bps YoY. FDE cited as ~279bps of decline. Temporary per management guidance.

Supported

Products portfolio growing 39% YoY to ₹150Cr run rate

Products ₹38Cr in Q2, implying ~₹150Cr annualized; 39% YoY growth confirmed; still only 4% of total

Supported

TMT expected healthy sequential growth in Q2

TMT grew 6% sequentially—positive but below company 5% average. Below prior call's tone.

Slightly overstated

What shifted on this call

  • Products momentum: ₹150Cr annualized run rate (+39% YoY). Cogentiq gaining enterprise traction (Microsoft Retail/CPG Partner of Year; AWS expansion).

  • Client concentration declining: Top 10 fell to 51.7% from 53.2% QoQ. 58 clients above ₹1M annual revenue. Healthy base broadening.

  • Net Revenue Retention improved: NRR 115% in Q2 vs 112% prior quarter. Land-and-expand working.

  • Gross margin recovery pushed to H2: Q2 came in 44% vs 46% prior-call implied. FDE drag higher than expected.

  • TMT recovery weaker: 6% sequential vs company 5% average. Hyperscaler capex shift cited; H2 recovery expected.

  • DSO increased to 76 days from 71: Larger deal mix, but working capital headwind. Normalization expected by year-end.

Bull and bear

The case for owning Fractal
  • $100M revenue scale validates enterprise AI consulting positioning in an era of rapid model proliferation and customer uncertainty.

  • Profit leverage +139% YoY despite gross margin compression proves SG&A discipline and operating leverage are real.

  • Client quality improving: NPS 76, NRR 115%, top 10 concentration declining. Deepening relationships, not chasing volume.

  • Healthcare +79% YoY and naturally high-margin. AI investment appetite in this sector is durable, not cyclical.

  • Products +39% YoY gaining enterprise traction. Path to higher-margin licensing revenue is tangible.

  • Strong balance sheet: ₹1,728 crore cash including ₹608 crore IPO proceeds. No debt, dry powder for FDE investment or M&A.

The case for caution
  • Gross margin 44% is structural. Recovery to 46%+ required in Q3/Q4. Miss on timing = miss on valuation thesis. Execution risk is material.

  • CPG (largest vertical, ~15% of revenue) growing 11% YoY amid consolidation and inflation. Sequential decline in Q2 concerning.

  • TMT only 6% sequential despite recovery positioning. Hyperscaler capex shift toward infrastructure could extend weakness into FY28.

  • Products only 4% of revenue. $100M target by FY27 end requires 50%+ sequential growth and 78% CAGR. Early-stage risk is high.

  • DSO increased to 76 days. Larger deal mix is positive long-term but payment term extension pressures working capital near-term.

  • Qure.ai restructuring—₹23Cr loss drag (23% of reported profit). Expected to normalize but timing uncertain.

How the street is positioned

Fractal's stock is trading at ₹809.45 in a bullish trend with increasing volume. It sits above its 20-day (₹744) and 50-day (₹764) moving averages, confirming upward momentum. Yet at −27.4% from its all-time high of ₹1,115, the stock retains material discount to peak, reflecting skepticism on near-term margin recovery and products execution.

From the 52-week low of ₹696.30, Fractal has recovered +16.25%, rewarding the $100M milestone and margin recovery narrative. RSI at 59.8 is neutral—neither overbought nor oversold—indicating room for upside if execution validates the H2 margin rebound story.

Ownership flows show FII buying strength. FII holdings ticked up +39 basis points quarter-over-quarter to 40.87%, a modest but consistent accumulation signal. DII holdings declined slightly (−99bps to 12.26%), suggesting some domestic profit-taking or rebalancing. Promoter stake remains steady at 16.97%. The FII buying on the dip supports conviction in the long-term AI thesis, but magnitude is incremental, not aggressive.

The debate

Ranked risks for a holder

What should concern a shareholder, ordered by severity

Gross margin recovery timing uncertain

High

Management guided Q3/Q4 recovery, but FDE deployment billing depends on client win velocity and project cadence. A Q3 miss breaks the margin expansion thesis entirely; implies 10–15% downside.

CPG vertical consolidation and macro drag

Medium

Largest vertical (~15% of revenue), growing 11% YoY vs 20% company average. Sequential decline in Q2. If H2 recovery stalls, overall growth trajectory misses consensus.

TMT sector relying on AI adoption acceleration

Medium

Only 6% sequential growth despite being recovery story. Hyperscaler capex pivot away from services could extend weakness into FY28, affecting 10%+ of revenue.

Products $100M roadmap execution

Medium

Requires 50%+ sequential growth and 78% CAGR from a 4% revenue base. Early-stage platform adoption is unpredictable. Miss would lower profitability profile and growth narrative.

DSO increase and working capital drag

Low-Medium

76 days vs 71 days prior. Larger deal mix is positive but extended payment terms compress cash conversion. Miss on normalization by year-end = ongoing drag on free cash flow.

Qure.ai loss dragging consolidated metrics

Low

₹23Cr loss = 23% of reported profit. Expected to ease, but timing uncertain. Doesn't affect core Fractal but weights reported profitability and NPM.

What to watch next quarter

Five catalysts that resolve the margin debate
  • 1 · Q3 gross margin recovery

    The hinge. Even recovery to 45% sequentially validates management narrative. Stall at 44% or compression = thesis break.

  • 2 · FDE deployment and revenue contribution

    Billable FDE headcount and revenue generation metrics. Are FDE-driven revenues hitting ₹50–100 Cr annually? If so, margin recovery becomes credible.

  • 3 · Large deals pipeline closure

    Management forming large deals team. First quarterly wins and run-rate ($5M+/quarter) would validate premium positioning and justify DSO increase.

  • 4 · Products portfolio velocity

    Cogentiq licensing wins and quarterly revenue run-rate. Currently ₹38Cr per quarter; need acceleration to $25M+ per quarter to track $100M target by FY27 end.

  • 5 · CPG and TMT stabilization

    Sequential growth inflection in these verticals. Recovery to company average (5%+) signals macro tailwind. Flat = sector-specific issues persist.

The one number to track from here

Gross margin. That's it. The quarter proves Fractal can scale revenue and leverage SG&A. The debate is execution on margin recovery. If Q3 gross margin recovers to 45% or higher, the stock re-rates up (implied upside 15–20% to ₹925–970). If it stays at 44%, downside risk to re-test 52-week lows at ₹696 is real (−14–15%). For now, the company delivered on scale. H2 will answer whether the AI talent investment pays off on the margin line.

Fractal is no longer a mid-market consulting shop. At ₹957 crore in quarterly revenue (~$115M USD), it has reached enterprise scale. The profit growth (+139% YoY) shows management can leverage fixed costs while investing in growth. But the 225 basis point gross margin compression is real, and the recovery guidance (Q3/Q4) is the hinge on which the entire valuation swings. The market has rewarded the milestone (+16% from lows) but hasn't regained full faith (−27% from ATH). For holders, the quarter is neither catastrophe nor triumph—it's a pause and a test. Q3 gross margin will tell you which direction the stock goes next.

Informational and educational content only. Not investment advice.